According to a recently published study in the Journal of Arthritis & Rheumatology, Baricitinib treatment shows no associations with arterial thrombotic events (ATE), congestive heart failure (CHF), and major adverse cardiovascular events (MACE), and very little associations with Deep vein thrombosis (DVT) and pulmonary embolism (PE).

A total of nine RA studies were used to extract the information. Six studies involved placebo comparison for up to 24 months. Four studies involved randomized dose comparison with information regarding 2-mg and 4-mg baricitinib and related long-term extension (LTE) data. The set of 'All-bari-RA' comprised all baricitinib exposures at any dose.

The analysis involved a total of 3492 participants. Regarding ATE, CHF, and MACE, no imbalance was noticed in the treatment versus placebo group. However, in the case of PE and DVT, the 4-mg baricitinib group showed six incidences, whereas the placebo exhibited no incidences. Both doses showed similar incidence rates across the event types. The rates were stable over time in the All-bari-RA analysis set. As this analysis involved a limited number of reported events, the more real-world studies involved characterization of rates of these, and other CV events will be continued.